Trials / Sponsors / Ryvu Therapeutics SA
Ryvu Therapeutics SA
Industry · 7 registered clinical trials — 4 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | RVU120 Rollover Study Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome | Phase 2 | 2025-12-15 |
| Recruiting | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) Non-Hodgkin Lymphoma, B-cell | Phase 2 | 2024-12-05 |
| Recruiting | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis Myelofibrosis | Phase 2 | 2024-09-19 |
| Active Not Recruiting | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | Phase 2 | 2024-01-23 |
| Recruiting | Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML Acute Myeloid Leukemia | Phase 2 | 2024-01-05 |
| Active Not Recruiting | RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2021-08-13 |
| Unknown | RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 1 | 2019-09-04 |